Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics
01/08/2024 05:17
TOKYO, Aug 1 (Reuters) - Japan's Otsuka Pharmaceutical
4578.T said on Thursday it would pay more than $1 billion to
acquire U.S.-based Jnana Therapeutics as it looks to expand its
drug pipeline.
Otsuka will pay $800 million to Jnana shareholders along
with up to $325 million in development and regulatory
milestones, the Japanese company said in a statement. The deal
is expected to be completed in the third quarter of this year.
(Reporting by Rocky Swift;Editing by Clarence Fernandez)
((rocky.swift@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug